主体导向疗法调节血液恶性瘤感染的先天免疫力
Qiong Wang1, Kristján Hermannsson1, Egill Másson2
1Faculty of Life and Environmental Sciences, Biomedical Center, University of Iceland, Reykjavik, Iceland.
Blood reviews
|December 17, 2024
概括
患有血液恶性瘤的患者面临高血流感染 (BSI) 和败血症的高风险. 主体防御 (HDP) 和免疫系统诱导剂 (ISI) 提供了一个有前途的主体导疗法 (HDT) 来预防这些严重的并发症.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 微生物学 微生物学
背景情况:
- 患有血液性恶性瘤 (HM) 的患者极易患有血流感染 (BSI) 和败血症,通常是由于化疗引起的粘膜炎.
- 治疗BSI的常规抗生素可能导致抗菌素耐药性 (AMR) 和肠道失生症,使治疗复杂化.
- 粘膜屏障的完整性对于预防免疫受损患者感染和败血症至关重要.
研究的目的:
- 审查宿主防御 (HDP) 和免疫系统诱导剂 (ISI) 作为宿主导疗法 (HDT) 的潜力,以预防HM患者的BSI和败血症.
- 突出维护粘膜屏障完整性的未经探索的治疗策略.
- 倡导开发新的ISI用于临床应用.
主要方法:
- 文献综述侧重于宿主防御 (HDP) 和免疫系统诱导剂 (ISI).
- 分析支粘膜屏障保护和感染预防的机制.
- 讨论常规抗生素治疗的当前挑战,包括AMR和失生症.
主要成果:
- HDP和ISI代表了一种可行的宿主导疗法 (HDT) 方法来增强先天免疫力.
- 这些药物可以保持粘膜屏障的完整性,这对于预防BSI和败血症至关重要.
- ISI为传统抗生素提供了潜在的替代品,减轻了AMR和失生症的风险.
结论:
- 主体防御 (HDP) 和免疫系统诱导剂 (ISI) 是有前途的预防血液感染 (BSI) 和毒症在血液恶性病患者.
- 需要对ISI进行进一步的研究,以了解其机制并优化其临床使用.
- 开发强效和安全的ISI对于在瘤学中推进宿主导疗法 (HDT) 至关重要.
相关概念视频
01:01Regulation of Hematopoietic Stem Cells
3.1K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.1K
01:27Tumor Immunotherapy
475
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
475
01:27Cytotoxic T Cells-mediated Immune Response
844
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
844
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
01:40Cell-mediated Immune Responses
66.9K
Overview
66.9K
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
141
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
141